What do we still not know about pantoprazole? Review article
Article Sidebar
Published:
Sep 30, 2015
Keywords:
pantoprazole, gastroesophageal reflux disease, nonerosive reflux disease
Main Article Content
Abstract
For years, due to its safety profile and effectiveness, pantoprazole has been one of the most effective proton pump inhibitors. However, in recent years, new research related to its effects on the metabolism of drugs shows also other possibilities of its use, e.g. in diabetes type 2 or in oncology, as a drugmodifying metabolism of other drugs.
Article Details
How to Cite
Waśko-Czopnik , D. (2015). What do we still not know about pantoprazole?. Medycyna Faktow (J EBM), 8(3(28), 51-55. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2296
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Brunner G., Athmann C., Schneider A.: Long-term, open label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment. Pharmacol. Ther. 2012; 36: 37-47.
2. Brunner G., Harke U.: Long-term therapy with pantoprazole in patients with peptic ulceration resist to extended high-dose reanitidine treatment. Aliment. Pharmacol. Ther. 1994; 8(supl. 1): 59-64.
3. Genta R.M.: Acid suppression and gastric atrophy: sifting fact from fiction. Gut 2009; 43: S35-38.
4. Dąbrowski A.: Skuteczność i bezpieczeństwo pantoprazolu (Nolpaza) w leczeniu pacjentów z chorobą refluksową przełyku – wyniki badania PAN-STAR. Gastroenterologia Praktyczna 2014; 1: 1-12.
5. Klikenberg-Knol E.C., Nelis F., Dent J. et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety an influence on gastric mucosa. Gastroenterology 2000; 119: 661-669.
6. Lamberts R., Brunner G., Solcia E.: Effects of very long (up to 10 years) proton pomp blockade on human gastric mucosa. Digestion 2001; 64: 205-213.
7. Kataz P.O., Gerson L.B., Vela M.F.: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013; 108: 308-328.
8. Fass R.: Erosive esophagitis and nonerosive reflux disease (NERD) – comparison of epidemiologic, physiologic and therapeutic characteristics. J. Clin. Gastroenterol. 2007; 41: 131-137.
9. Fass R., Shapiro M., Dekel R. et al.: Systematic review: proton pump inhibitor failure in gastroesophageal reflux disease – where next? Aliment. Pharmacol. Ther. 2005; 22: 79-94.
10. Ji-Xiang Z., Meng-Yao J., Jia S. et al.: Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J. Gastroenterol. 2013; 19(45): 8408-8419.
11. Wedemeyer R.S., Blume H.: Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 [doi:10.1007/s40264-014-0144-0].
12. Gerson L.B., Triadafilopoulos G.: Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur. J. Gastroenterol. Hepatol. 2001; 13(5): 611-616.
13. Laine L.: Proton pomp inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm? Gastroenterology 2011: 140(3): 769-772.
14. Kwok C.S., Loke Y.K.: Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Aliment Pharmacol. Ther. 2010; 31(8): 810-823.
15. Duursema L., Muller F.O., Schall R., Middle M.V. et al.: Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br. J. Clin. Pharmac. 1995; 39: 700-703.
16. Gugler R., Hartmann M., Rudi J. et al.: Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br. J. Clin. Pharmacol. 1996; 42: 249-252.
17. Ward R.M., Kearns G.L., Brinda T. et al.: A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescets aged 6 through 16 years with GERD. J. Clin. Pharmacol. 2011; 51(6): 876-887.
18. Monnikes H., Heading R.C., Schmitt H. et al.: Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. World J. Gastroenterol. 2011; 21: 17(27): 3235-3231.
19. Inci F., Atmaca M., Ozturk M. et al.: Pantoprazole may improve beta cell function and diabetes mellitus. J. Endocrinol. Invest. 2014; 37(5): 449-454.
20. González-Ortiz M., Martínez-Abundis E., Mercado-Sesma A.R. et al.: Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2015; 108(1): e11.
21. Brana I., Ocana A., Chen E.X. et al.: Phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest. New Drugs 2014; 32(6): 1269-1277.
22. Zhang B., Yang Y., Shi X. et al.: Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition. Cancer Lett. 2015; 28; 356(2 Pt B): 704-712.
23. Shen W., Zou X., Chen M. et al.: Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho LRP6 expression in Wnt/β-catenin signaling. Oncol. Rep. 2013; 30(2): 851-855.
24. Tan Q., Joshua A.M., Saggar J.K.: Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br. J. Cancer 2015; 3; 112(5): 832-840.
2. Brunner G., Harke U.: Long-term therapy with pantoprazole in patients with peptic ulceration resist to extended high-dose reanitidine treatment. Aliment. Pharmacol. Ther. 1994; 8(supl. 1): 59-64.
3. Genta R.M.: Acid suppression and gastric atrophy: sifting fact from fiction. Gut 2009; 43: S35-38.
4. Dąbrowski A.: Skuteczność i bezpieczeństwo pantoprazolu (Nolpaza) w leczeniu pacjentów z chorobą refluksową przełyku – wyniki badania PAN-STAR. Gastroenterologia Praktyczna 2014; 1: 1-12.
5. Klikenberg-Knol E.C., Nelis F., Dent J. et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety an influence on gastric mucosa. Gastroenterology 2000; 119: 661-669.
6. Lamberts R., Brunner G., Solcia E.: Effects of very long (up to 10 years) proton pomp blockade on human gastric mucosa. Digestion 2001; 64: 205-213.
7. Kataz P.O., Gerson L.B., Vela M.F.: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013; 108: 308-328.
8. Fass R.: Erosive esophagitis and nonerosive reflux disease (NERD) – comparison of epidemiologic, physiologic and therapeutic characteristics. J. Clin. Gastroenterol. 2007; 41: 131-137.
9. Fass R., Shapiro M., Dekel R. et al.: Systematic review: proton pump inhibitor failure in gastroesophageal reflux disease – where next? Aliment. Pharmacol. Ther. 2005; 22: 79-94.
10. Ji-Xiang Z., Meng-Yao J., Jia S. et al.: Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J. Gastroenterol. 2013; 19(45): 8408-8419.
11. Wedemeyer R.S., Blume H.: Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 [doi:10.1007/s40264-014-0144-0].
12. Gerson L.B., Triadafilopoulos G.: Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur. J. Gastroenterol. Hepatol. 2001; 13(5): 611-616.
13. Laine L.: Proton pomp inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm? Gastroenterology 2011: 140(3): 769-772.
14. Kwok C.S., Loke Y.K.: Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Aliment Pharmacol. Ther. 2010; 31(8): 810-823.
15. Duursema L., Muller F.O., Schall R., Middle M.V. et al.: Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br. J. Clin. Pharmac. 1995; 39: 700-703.
16. Gugler R., Hartmann M., Rudi J. et al.: Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br. J. Clin. Pharmacol. 1996; 42: 249-252.
17. Ward R.M., Kearns G.L., Brinda T. et al.: A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescets aged 6 through 16 years with GERD. J. Clin. Pharmacol. 2011; 51(6): 876-887.
18. Monnikes H., Heading R.C., Schmitt H. et al.: Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. World J. Gastroenterol. 2011; 21: 17(27): 3235-3231.
19. Inci F., Atmaca M., Ozturk M. et al.: Pantoprazole may improve beta cell function and diabetes mellitus. J. Endocrinol. Invest. 2014; 37(5): 449-454.
20. González-Ortiz M., Martínez-Abundis E., Mercado-Sesma A.R. et al.: Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2015; 108(1): e11.
21. Brana I., Ocana A., Chen E.X. et al.: Phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest. New Drugs 2014; 32(6): 1269-1277.
22. Zhang B., Yang Y., Shi X. et al.: Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition. Cancer Lett. 2015; 28; 356(2 Pt B): 704-712.
23. Shen W., Zou X., Chen M. et al.: Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho LRP6 expression in Wnt/β-catenin signaling. Oncol. Rep. 2013; 30(2): 851-855.
24. Tan Q., Joshua A.M., Saggar J.K.: Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br. J. Cancer 2015; 3; 112(5): 832-840.